Cost-Effectiveness Analysis of Carfilzomib vs Bortezomib in Relapsed/Refractory Multiple Myeloma in Iran.
OBJECTIVES Multiple myeloma, the second most common hematologic malignancy, primarily affects older adults. Proteasome inhibitors such as carfilzomib and bortezomib are key treatment options. Because of high costs, disease progression, and differences in drug outcomes, cost-effectiveness evaluations are crucial for hea...